Imsidolimab vs SHR-1139
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-36 receptor · full Psoriasis pipeline
Imsidolimab
Developed by Vanda Pharmaceuticals under a licence from AnaptysBio
NCT05352893 · Phase 3 · completed
GEMINI-1 was a randomized, double-blind, placebo-controlled Phase 3 trial in 45 patients with a generalized pustular psoriasis flare, randomized 1:1:1 to a single IV dose of imsidolimab 750 mg, 300 mg or placebo. The primary endpoint was GPPPGA 0 or 1 (clear or almost clear) at week 4: 53.3% with 750 mg vs 13.3% with placebo (p=0.0131), so the primary was met. The 300 mg arm had the same response count (8 of 15) on CT.gov, but the release gives no test for it. Sources: CT.gov posted results and the AnaptysBio press release filed on SEC Form 8-K.
Reported efficacy
Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) (Week 4): GPPPGA 0/1 at week 4: imsidolimab 750 mg IV 53.3% (8/15) vs placebo 13.3% (2/15), p=0.0131; 300 mg IV 8/15 (CT.gov, no test posted for 300 mg) (AnaptysBio release, 9 Oct 2023, SEC 8-K). (met)
Result source: NCT05352893
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
NCT07051538 · Phase 1 · completed
This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: December 2026 · NCT07719530 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Imsidolimab | SHR-1139 |
|---|---|---|
| PASI 75 | —Not reported | —Not reported |
| PASI 90 | —Not reported | —Not reported |
| PASI 100 | —Not reported | —Not reported |
| sPGA 0/1 | —Not reported | —Not reported |
| DLQI, change | —Not reported | —Not reported |
PASI 75
- Imsidolimab
- —Not reported
- SHR-1139
- —Not reported
PASI 90
- Imsidolimab
- —Not reported
- SHR-1139
- —Not reported
PASI 100
- Imsidolimab
- —Not reported
- SHR-1139
- —Not reported
sPGA 0/1
- Imsidolimab
- —Not reported
- SHR-1139
- —Not reported
DLQI, change
- Imsidolimab
- —Not reported
- SHR-1139
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Imsidolimab: registry results are on file for Psoriasis, but their comparison mappings are not yet available.
SHR-1139: no structured comparison results are available for Psoriasis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Imsidolimab's landscape · SHR-1139's landscape